Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).

这个项目的重点是发现治疗急性髓系白血病(AML)的一流候选药物，基于一种识别新的遗传靶点的新方法。AML是一种高风险的血液系统恶性肿瘤，具有高度未满足的需求。现有的治疗选择有限，特别是对于不符合强化化疗条件或复发的患者。AML很罕见，约占所有癌症的1%。在英国，2023年将有大约3100名患者被诊断为急性髓细胞白血病(CRUK)。45岁以上的人发病率通常更高。老年患者的死亡率很高，英国每年约有2700名患者死于急性髓细胞白血病。20岁以上的AML患者的5年相对存活率为28%。由于耐药性和复发而导致的不良结果在AML患者中很常见。该项目将结合英国和瑞士两家中小企业独特的基于人工智能的生物信息学平台和专业知识，利用人工智能、机器学习和合成生物学来解决AML问题，以促进对新疾病的理解、新靶点的识别和新药物的发现。

This project is focused on the discovery of first-in-class drug candidates for the treatment of Acute Myeloid Leukaemia (AML) based on a novel approach to identifying novel genetic targets.AML is a high-risk hematologic malignancy with a high unmet need. Limited treatment options exist, particularly for patients who are ineligible for intensive chemotherapy or experience relapse. AML is rare, making up around 1% of all cancers. In the UK around 3,100 patients will be diagnosed with AML in 2023 (CRUK). Incidence rates are typically higher for those over 45\. Mortality in older patients is high, around 2,700 patients in the UK will die annually from AML. The 5-year relative survival rate for people over twenty with AML is 28%. Poor outcomes due to drug resistance and relapse is common in patients with AML.This project will combine the unique AI-based bioinformatics platforms and expertise of two SMEs, based in the UK and Switzerland, to tackle the problem of AML using AI, machine learning and synthetic biology to advance new disease understanding, novel target identification, and novel drug discovery.